Free Trial
NYSE:BXLT

(BXLT) (BXLT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$46.02
$46.02
50-Day Range
N/A
52-Week Range
$29.83
$46.52
Volume
N/A
Average Volume
12.66 million shs
Market Capitalization
N/A
P/E Ratio
15.49
Dividend Yield
N/A
Price Target
N/A
BXLT stock logo

About (BXLT) Stock (NYSE:BXLT)

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

BXLT Stock News Headlines

AnyMind Group Inc 5027
IDICO Corp JSC Ordinary Shares IDC
Hana Financial Group Inc 086790
See More Headlines
Receive BXLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (BXLT) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/28/2016
Today
6/01/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

BXLT Stock Analysis - Frequently Asked Questions

How were (BXLT)'s earnings last quarter?

(BXLT) (NYSE:BXLT) posted its earnings results on Thursday, April, 28th. The biotechnology company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. The biotechnology company had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.47 billion. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the business posted $0.40 EPS.

Is (BXLT) a good dividend stock?

(BXLT) (NYSE:BXLT) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 9.43%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for BXLT.

What other stocks do shareholders of (BXLT) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (BXLT) investors own include Baxter International (BAX), Hawkins (HWKN), AbbVie (ABBV), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Alibaba Group (BABA), Bank of America (BAC), Edwards Lifesciences (EW), Gilead Sciences (GILD) and Micron Technology (MU).

This page (NYSE:BXLT) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners